Melflufen-Based Combination Therapy for Resistant Myeloma
Combination Therapy With Selinexor, Lenalidomide, and Dexamethasone in Resistant Myeloma
Orphan Drug Designation Granted to Immunotherapy for Multiple Myeloma
ESMO 2019: First-Line Versus Non–First-Line Bortezomib in Asian Patients With Myeloma
Supportive Care for Older Adults With Myeloma: Underuse of Guideline Recommendations?
ASCT in Myeloma: Will It Be Transplanted by Other Treatments?
Serum Immune Marker and Progression From MGUS to Multiple Myeloma
Early-Phase Study of Iberdomide Plus Dexamethasone for Resistant Multiple Myeloma
Insights on Individualizing Treatment of Patients with Multiple Myeloma
Redefining Value Propositions and Managed Care Considerations in Multiple Myeloma
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
City of Hope Comprehensive Cancer Center
Roswell Park Cancer Institute
International Myeloma Foundation (IMF)
The Leukemia and Lymphoma Society
Multiple Myeloma Research Foundation (MMRF)
NCCN Guidelines for Patients: Multiple Myeloma